April 10, 2023:KYJY won the title of "Specialized & Innovative SME

April 14, 2023：KYJYlatest research results were presented at the AACR Annual Meeting in the United States

December 19, 2022:KYJY WON the “High-tech Enterprise Certificate”

December 18, 2022: KYJY won the title of "Innovative Small and Medium-sized Enterprise" in Shenzhen

November 10, 2022：Shenzhen Enduring has been on the list —— The Top 10 most growing companies of Antibody drugs ( assessed by Shanghai BioPharmaceutics Industry Association）

May 12, 2022: "A Long Acting B Cell Depleting BiTE (Bi-Specific T Cell Engager) Significantly Ameliorated EAE Symptoms without Potential CRS Risk" (ID# 8386) will be presented as a Late Breaking Poster at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers in National Harbor, Maryland.

While the posters may be displayed starting on Wednesday, June 1st, the official poster session will take place on Thursday, June 2nd at 5-7pm.


Apr. 12, 2022: Bispecific ADC pipeline JY201 was presented at 2022 AACR meeting

November 08, 2021: Dr. Wen (CSO) presented JY108 candidate at the 15th ISNI Congress (International Society of Neuroimmunology) International Conference

September 18, 2021: Shenzhen Enduring completed the Series A financing (http://mp.weixin.qq.com/s/NmNXFs6OuPryGgm0S-x_Zg), which was led by Guozhong Capital

July 28, 2021: Shenzhen Enduring relocated to a new address due to business expansion: B1105, Building 1, Yinxing Zhijie Phase II, No. 1301-76, Xinlan Community Sightseeing Road, Guanlan Street, Longhua District, Shenzhen

July 20, 2021: Shenzhen Enduring's core technology platform patent was granted in the United States

April 09, 2021: Shenzhen Enduring presented the company's pipeline JY102 at the AACR International Conference

November 10, 2020: Shenzhen Enduring won the Top 10 Innovation Award at the 4th SATOL Life Science and Entrepreneurship Competition organized by the Chinese Academy of Engineering and Zhejiang University

October 1, 2020: Shenzhen Enduring won the Biotechnology Excellence Award at First Zhichuang Cup competition held in Shenzhen

September 1, 2019:Shenzhen Enduring participated in the National Innovation and Entrepreneurship Competition and won the first prize in Longhua District

December 31, 2018: Shenzhen Enduring's Laboratory officially opened for business in Silver Star Technology Building, Longhua District, Shenzhen

September 5, 2018: Pre-A financing completed

July 31, 2018: Shenzhen Enduring was incorporated in Shenzhen

November 10, 2022：Shenzhen Enduring has been on the list —— The Top 10 most growing companies of Antibody drugs ( assessed by Shanghai BioPharmaceutics Industry Association）

May 12, 2022: "A Long Acting B Cell Depleting BiTE (Bi-Specific T Cell Engager) Significantly Ameliorated EAE Symptoms without Potential CRS Risk" (ID# 8386) will be presented as a Late Breaking Poster at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers in National Harbor, Maryland.

While the posters may be displayed starting on Wednesday, June 1st, the official poster session will take place on Thursday, June 2nd at 5-7pm.


Apr. 12, 2022: Bispecific ADC pipeline JY201 was presented at 2022 AACR meeting

November 08, 2021: Dr. Wen (CSO) presented JY108 candidate at the 15th ISNI Congress (International Society of Neuroimmunology) International Conference

September 18, 2021: Shenzhen Enduring completed the Series A financing (http://mp.weixin.qq.com/s/NmNXFs6OuPryGgm0S-x_Zg), which was led by Guozhong Capital

July 28, 2021: Shenzhen Enduring relocated to a new address due to business expansion: B1105, Building 1, Yinxing Zhijie Phase II, No. 1301-76, Xinlan Community Sightseeing Road, Guanlan Street, Longhua District, Shenzhen

July 20, 2021: Shenzhen Enduring's core technology platform patent was granted in the United States

April 09, 2021: Shenzhen Enduring presented the company's pipeline JY102 at the AACR International Conference

November 10, 2020: Shenzhen Enduring won the Top 10 Innovation Award at the 4th SATOL Life Science and Entrepreneurship Competition organized by the Chinese Academy of Engineering and Zhejiang University

October 1, 2020: Shenzhen Enduring won the Biotechnology Excellence Award at First Zhichuang Cup competition held in Shenzhen

September 1, 2019:Shenzhen Enduring participated in the National Innovation and Entrepreneurship Competition and won the first prize in Longhua District

December 31, 2018: Shenzhen Enduring's Laboratory officially opened for business in Silver Star Technology Building, Longhua District, Shenzhen

September 5, 2018: Pre-A financing completed

July 31, 2018: Shenzhen Enduring was incorporated in Shenzhen

Shen Zhen LTD recently announced the completion of Series A Financing. The fund raised will be used to move one PEGylated bispecific antibody into IND filing and clinical trial and build several PEGylated BsADC pipelines.

Shenzhen Enduring Biotech Co., Ltd. moves to a new location.
Silver Star Intelligent Community II, Suite 1105, Building 1B, 1301-76 Guanguang Road, Guanlan, Longhua District, Shenzhen, P.R. China 518110